These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 28480639)

  • 1. Pyrimethamine significantly lowers cerebrospinal fluid Cu/Zn superoxide dismutase in amyotrophic lateral sclerosis patients with SOD1 mutations.
    Lange DJ; Shahbazi M; Silani V; Ludolph AC; Weishaupt JH; Ajroud-Driss S; Fields KG; Remanan R; Appel SH; Morelli C; Doretti A; Maderna L; Messina S; Weiland U; Marklund SL; Andersen PM
    Ann Neurol; 2017 Jun; 81(6):837-848. PubMed ID: 28480639
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pyrimethamine decreases levels of SOD1 in leukocytes and cerebrospinal fluid of ALS patients: a phase I pilot study.
    Lange DJ; Andersen PM; Remanan R; Marklund S; Benjamin D
    Amyotroph Lateral Scler Frontotemporal Degener; 2013 Apr; 14(3):199-204. PubMed ID: 22985433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Wild-type Cu/Zn-superoxide dismutase is misfolded in cerebrospinal fluid of sporadic amyotrophic lateral sclerosis.
    Tokuda E; Takei YI; Ohara S; Fujiwara N; Hozumi I; Furukawa Y
    Mol Neurodegener; 2019 Nov; 14(1):42. PubMed ID: 31744522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gender difference in levels of Cu/Zn superoxide dismutase (SOD1) in cerebrospinal fluid of patients with amyotrophic lateral sclerosis.
    Frutiger K; Lukas TJ; Gorrie G; Ajroud-Driss S; Siddique T
    Amyotroph Lateral Scler; 2008 Jun; 9(3):184-7. PubMed ID: 18574763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening for inhibitors of the SOD1 gene promoter: pyrimethamine does not reduce SOD1 levels in cell and animal models.
    Wright PD; Huang M; Weiss A; Matthews J; Wightman N; Glicksman M; Brown RH
    Neurosci Lett; 2010 Oct; 482(3):188-92. PubMed ID: 20638444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 1-2 Trial of Antisense Oligonucleotide Tofersen for
    Miller T; Cudkowicz M; Shaw PJ; Andersen PM; Atassi N; Bucelli RC; Genge A; Glass J; Ladha S; Ludolph AL; Maragakis NJ; McDermott CJ; Pestronk A; Ravits J; Salachas F; Trudell R; Van Damme P; Zinman L; Bennett CF; Lane R; Sandrock A; Runz H; Graham D; Houshyar H; McCampbell A; Nestorov I; Chang I; McNeill M; Fanning L; Fradette S; Ferguson TA
    N Engl J Med; 2020 Jul; 383(2):109-119. PubMed ID: 32640130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ALS patients with mutations in the SOD1 gene have an unique metabolomic profile in the cerebrospinal fluid compared with ALS patients without mutations.
    Wuolikainen A; Andersen PM; Moritz T; Marklund SL; Antti H
    Mol Genet Metab; 2012 Mar; 105(3):472-8. PubMed ID: 22264771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trial of Antisense Oligonucleotide Tofersen for
    Miller TM; Cudkowicz ME; Genge A; Shaw PJ; Sobue G; Bucelli RC; Chiò A; Van Damme P; Ludolph AC; Glass JD; Andrews JA; Babu S; Benatar M; McDermott CJ; Cochrane T; Chary S; Chew S; Zhu H; Wu F; Nestorov I; Graham D; Sun P; McNeill M; Fanning L; Ferguson TA; Fradette S;
    N Engl J Med; 2022 Sep; 387(12):1099-1110. PubMed ID: 36129998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Misfolded superoxide dismutase-1 in CSF from amyotrophic lateral sclerosis patients.
    Zetterström P; Andersen PM; Brännström T; Marklund SL
    J Neurochem; 2011 Apr; 117(1):91-9. PubMed ID: 21226712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cerebrospinal fluid neurofilament light levels in amyotrophic lateral sclerosis: impact of SOD1 genotype.
    Zetterberg H; Jacobsson J; Rosengren L; Blennow K; Andersen PM
    Eur J Neurol; 2007 Dec; 14(12):1329-33. PubMed ID: 17903209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Copper Homeostasis as a Therapeutic Target in Amyotrophic Lateral Sclerosis with SOD1 Mutations.
    Tokuda E; Furukawa Y
    Int J Mol Sci; 2016 Apr; 17(5):. PubMed ID: 27136532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SOD1 in neurotoxicity and its controversial roles in SOD1 mutation-negative ALS.
    Hayashi Y; Homma K; Ichijo H
    Adv Biol Regul; 2016 Jan; 60():95-104. PubMed ID: 26563614
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oxidative stress and metal content in blood and cerebrospinal fluid of amyotrophic lateral sclerosis patients with and without a Cu, Zn-superoxide dismutase mutation.
    Ihara Y; Nobukuni K; Takata H; Hayabara T
    Neurol Res; 2005 Jan; 27(1):105-8. PubMed ID: 15829169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Superoxide dismutase concentration and activity in familial amyotrophic lateral sclerosis.
    Bowling AC; Barkowski EE; McKenna-Yasek D; Sapp P; Horvitz HR; Beal MF; Brown RH
    J Neurochem; 1995 May; 64(5):2366-9. PubMed ID: 7722523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations.
    Mackenzie IR; Bigio EH; Ince PG; Geser F; Neumann M; Cairns NJ; Kwong LK; Forman MS; Ravits J; Stewart H; Eisen A; McClusky L; Kretzschmar HA; Monoranu CM; Highley JR; Kirby J; Siddique T; Shaw PJ; Lee VM; Trojanowski JQ
    Ann Neurol; 2007 May; 61(5):427-34. PubMed ID: 17469116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutational analysis of the Cu/Zn superoxide dismutase gene in a Catalan ALS population: should all sporadic ALS cases also be screened for SOD1?
    Gamez J; Corbera-Bellalta M; Nogales G; Raguer N; García-Arumí E; Badia-Canto M; Lladó-Carbó E; Alvarez-Sabín J
    J Neurol Sci; 2006 Aug; 247(1):21-8. PubMed ID: 16674979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study.
    Miller TM; Pestronk A; David W; Rothstein J; Simpson E; Appel SH; Andres PL; Mahoney K; Allred P; Alexander K; Ostrow LW; Schoenfeld D; Macklin EA; Norris DA; Manousakis G; Crisp M; Smith R; Bennett CF; Bishop KM; Cudkowicz ME
    Lancet Neurol; 2013 May; 12(5):435-42. PubMed ID: 23541756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progressive impairment of CaV1.1 function in the skeletal muscle of mice expressing a mutant type 1 Cu/Zn superoxide dismutase (G93A) linked to amyotrophic lateral sclerosis.
    Beqollari D; Romberg CF; Dobrowolny G; Martini M; Voss AA; Musarò A; Bannister RA
    Skelet Muscle; 2016; 6():24. PubMed ID: 27340545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human Cu/Zn superoxide dismutase (SOD1) overexpression in mice causes mitochondrial vacuolization, axonal degeneration, and premature motoneuron death and accelerates motoneuron disease in mice expressing a familial amyotrophic lateral sclerosis mutant SOD1.
    Jaarsma D; Haasdijk ED; Grashorn JA; Hawkins R; van Duijn W; Verspaget HW; London J; Holstege JC
    Neurobiol Dis; 2000 Dec; 7(6 Pt B):623-43. PubMed ID: 11114261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disease-related changes in the cerebrospinal fluid metabolome in amyotrophic lateral sclerosis detected by GC/TOFMS.
    Wuolikainen A; Moritz T; Marklund SL; Antti H; Andersen PM
    PLoS One; 2011 Apr; 6(4):e17947. PubMed ID: 21483737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.